Seeking Alpha

487371

487371
Send Message
View as an RSS Feed
View 487371's Comments BY TICKER:
Latest  |  Highest rated
  • Trading halt for NPS Pharma [View news story]
    anyone out there have an explanation why NASDAQ chooses to halt trading for things like this?
    Sep 12, 2014. 08:50 AM | Likes Like |Link to Comment
  • FDA clears Keryx's ferric citrate, trading halted [View news story]
    (Actually, there was little uncertainty regarding the value of this drug amongst nephrologists).
    Sep 5, 2014. 02:40 PM | 1 Like Like |Link to Comment
  • Keryx to resume trading [View news story]
    Guess biodoubt isn't familiar with CRD patients, for whom most medicines can have serious side-effects
    Sep 5, 2014. 02:22 PM | Likes Like |Link to Comment
  • Keryx to resume trading [View news story]
    Can't imagine why the market seems upset with the need for inclusion of a warning label. This drug represents a breakthrough for the condition for which it is prescribed. Such patients are under constant monitoring for their overall condition of kidney failure, and, as such, are of no apparent risk of toxicity. The warning serves as a reminder for them to maintain medical surveillance.
    The whole thing is a plus!
    Sep 5, 2014. 01:57 PM | 1 Like Like |Link to Comment
  • Lilly basal insulin beats Lantus [View news story]
    most likely, the minor differences cited are of little, if any, clinical significance related to overall health. Likely that they are simply an attempt by Lilly to recapture a patent monopoly on insulin products, as generics will be replacing the current novalog/humalog price-fixing scheme. They hope that the medico-legal system will force doctors to prescribe these "new" products based on their (likely) hyped results.
    Sep 5, 2014. 08:26 AM | Likes Like |Link to Comment
  • Are Investors Overestimating The Market For MannKind's Afrezza? [View article]
    Excellent article with realistic perspective. As a long-term T1 (55 yrs), and physician as well, I find all points of discussion pertinent, unbiased, and well covered.
    A few considerations I would add are the following.
    First, there is no data that I've seen regarding changes of absorption characteristics with, eg, the common cold/URI/acute bronchitis, etc. It might be problematic for patients to have to switch to unfamiliar administration techniques every time such a problem occurs. Anyone see anything reported on this subject?
    Second, it is likely that there will be significant stock dilution in the near future, in order to cover the costs of extensive marketing process necessary to convince physicians to switch to treatment regimens for their patients to a medication with which they are unfamiliar. As I usually dealt with any newly introduced therapy in my field, I'd wait 5-10 yrs. to wait for reports of ill effects before switching from something that was tried and true. Anyone remember Vioxx? :-)
    An additional note regarding "list" pricing of insulin preps: standard insulin preps (Humulin: ~$90/bottle) and insulin analogues (Novalog: ~$200/bottle). Also realize that many pharmacies add on arbitrary additions to these prices, sometimes to inordinate degrees (like double).
    Jun 28, 2014. 01:12 PM | 1 Like Like |Link to Comment
  • Are Investors Overestimating The Market For MannKind's Afrezza? [View article]
    genes and epigenes are probably far more important than anyone has yet determined, especially regarding T1. Please don't comment based on lack of knowledge
    Jun 28, 2014. 11:53 AM | Likes Like |Link to Comment
  • MannKind And Afrezza's NDA Evaluation: What Is The Real Justification For The Advisory Committee? [View article]
    Fairly comprehensive article, but certain amount of bias present which should be considered.
    I have been type I diabetic for > 60 yrs, and am, as well, a physician. One significant treatment modality which has been completely ignored in this article is the use of the insulin pump. This is a highly reliable means of insulin delivery, requiring a single, near painless injection only once in 3 days, which obviates much of what you discuss about the "inconveniences" of subcutaneous insulin administration. This method has, to date, been shown to provide the best blood sugar control achievable, and thereby is best at avoiding the multitude of long-term complications of the disease.

    I would add that the pain associated with the injections for inserting the pump is less than that of the finger-sticks necessary to check on the blood glucose level (though there are other, less reliable but painless means of determining these levels). The finger-sticks, themselves, are also near-painless.
    Also exaggerated in this article is the discussion of local trauma at injection sites, which is virtually non-existent with current 30 and 31 gauge hypodermic needles, which are about the diameter of a very fine sewing needle. The likelihood of damage to local nerves and capillaries with these devices is near nil, while damage to any significant subcutaneous structures is virtually impossible. (I would add that trying to self inject in a moving vehicle is comparable to using a cell phone while driving :-)---though it would be quite simple to do with an insulin pump).

    It is also likely that any upper respiratory infection will interfere with inhalational administration of insulin, which would necessitate reverting to an injection style of administration. Switching methods of glycemic control in unpredictable fashion would never be good for treatment of diabetes.

    My personal thoughts about this product are that, if approved, it will have limited prescribing for small subsets of diabetics for whom it might be more appropriate than the tried-and-true methods. As a result, it might also have a prohibitive price, which will deter insurers from allowing its use except in carefully limited circumstances.

    My recommendation is that if you own this stock, SELL on approval!

    Mar 28, 2014. 11:52 AM | 2 Likes Like |Link to Comment
  • Halozyme cellulite treatment performs well in study [View news story]
    Who are they kidding? A "treatment" for cellulite?
    Maybe HGH would work, but don't get sucked into this product except for pump & dump.
    Remember HEB?
    Mar 25, 2014. 09:44 AM | Likes Like |Link to Comment
  • Yahoo: Some ads spread malware [View news story]
    -----and I got hit with malware twice recently from AOL. The mals are getting more & more devious
    Jan 6, 2014. 08:32 AM | Likes Like |Link to Comment
  • CytRx reports positive top-line data from aldoxorubicin STS trial [View news story]
    remarkable what effect on share price results from a barely significant clinical effect for any cancer therapy! Does anyone remember DNDN? SRPT is another one with insignificant data (but it took a long time for the FDA to figure that one out.
    Dec 11, 2013. 09:33 AM | Likes Like |Link to Comment
  • The Pay-TV industry: Something has to give [View news story]
    agree with all of the above: Has anyone tried over-air HD broadcasts?
    All the networks available, with better picture and sound quality than cable or DISH or Fibre-optic, and all free! And time to read books, too.
    Must be up to "700 channels and nothing to watch" by this time!
    Dec 5, 2013. 08:52 AM | Likes Like |Link to Comment
  • Model S clears safety regulators in Germany [View news story]
    of course germany would clear the TSLA! How else can they ignore the recent Porsche fire?
    Dec 3, 2013. 09:23 AM | 3 Likes Like |Link to Comment
COMMENTS STATS
13 Comments
8 Likes